Skip to main content

Advertisement

Fig. 5 | Respiratory Research

Fig. 5

From: Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

Fig. 5

Annual rate of decline in FVC in the INPULSIS trials and their open-label extension INPULSIS-ON [26]. Annual rate of decline in FVC over 52 weeks in INPULSIS and over 192 weeks in INPULSIS-ON. Patients who took nintedanib in an INPULSIS trial continued nintedanib in INPULSIS-ON. Patients who took placebo in an INPULSIS trial initiated nintedanib in INPULSIS-ON. Error bars show the standard error. FVC, forced vital capacity. Republished with permission of Lancet Respir Med, from Long-term treatment with nintedanib in patients with idiopathic pulmonary fibrosis: results from INPULSIS-ON, Crestani et al., doi: https://doi.org/10.1016/S2213-2600(18)30339-4, 2018; permission conveyed through Copyright Clearance Center, Inc.

Back to article page